Prostate cancer and antidepressants: A nationwide population-based nested case-control study.

Abstract

BACKGROUND:

We aimed to evaluate the association between antidepressant and prostate cancer by comparing exposures to antidepressants between those with and without prostate cancer.

METHODS:

A nationwide insurance claims database was used to identify our case subjects. Age- and gender-matched controls were selected at a 1:5 ratio. Conditional logistic regression model was used.

RESULTS:

11,515 patients with prostate cancer were identified and matched with 55,373 controls. No increased associations between prostate cancer and most classes of antidepressants were found. However, a positive association with adjusted odds ratios ranged from 1.20 to 1.35 was noted in different doses of imipramine. Nevertheless, this association became statistically insignificant at higher cumulative doses.

CONCLUSIONS:

Our results indicate that there is no association between mechanistically dissimilar antidepressants and increased hazard for prostate cancer.

• Authors: Wei-Yu Lin, Vincent Chin-Hung Chen, Wei-Che Chiu, Samantha J Yim, Peter T Ho, Roger S McIntyre, Mong-Liang Lu, Shui-I Wu
• Journal: Journal of affective disorders (J Affect Disord) Vol. 227 Pg. 834-839 (02 2018) ISSN: 1573-2517 [Electronic] Netherlands
• PMID: 29689697 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2017 Elsevier B.V. All rights reserved.

Chemical References

• Antidepressive Agents
• Imipramine

Topics

• Adult
• Aged
• Aged, 80 and over
• Antidepressive Agents (adverse effects, therapeutic use)
• Case-Control Studies
• Correlation of Data
• Databases, Factual
• Dose-Response Relationship, Drug
• Humans
• Imipramine (adverse effects, therapeutic use)
• Insurance Claim Review
• Logistic Models
• Male
• Middle Aged
• Odds Ratio
• Prostatic Neoplasms (chemically induced)
• Taiwan